Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price1,142.70 INR
Fair value928.38Our model only; no analyst estimate to cross-check.
Ethical score91.3/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-16Read Markup1,110.00+2.9% to today ✓Distribution gives way to Markup after a 6% rise in 2 weeks
2026-10-02Read Distribution1,051.40+8.7% to today Markup gives way to Distribution after an 11% slide in 13 weeks
2026-07-02Read Markup1,187.60-3.8% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Infosys Ltd holds its Markup at $1,142.70. Consolidating, no directional conviction, held for 9 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 9 days
Price at the screen
$1,142.70
Valuation
13.91 trailing · 12.84 forward price to earnings
Values screen
PASS· score 91.3
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.88%
Below 33%
Interest-bearing debt is just 5.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.23%
Below 33%
Cash held in interest-bearing accounts and securities is 14.2% of assets, under the one-third limit.
Pass
Receivables
1.96%
Below 49%
Money owed to the company is 2.0% of assets, under the 49% limit.
Pass
Revenue purity
0.23%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Infosys clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 6%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when INFY.NS's ethical verdict changes
Today INFY.NS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our 928.38 INR fair value estimate, 6.60% revenue growth.
Fair value range in INR, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 23.1% above the base estimate.
Where our models see it going: fair-value estimate 928.38 INR, with a range of 849.13 INR to 1,415.22 INR, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 12.8x forward earnings, the price already runs ahead of the business. It trades 23% above our 928.38 INR fair value, so you would be buying at a premium, not a discount.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
INFY.NS trades on NSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup$1,163.00+4.8%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461.
2026-10-16Markup · changed$1,110.00+5.6%Entry 13
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461.
2026-08-24Markup$1,187.60+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461.
2026-07-23Markup$1,187.60+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22Markup$1,187.60+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21Markup$1,187.60+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Markup$1,187.60+0.0%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Markup$1,187.60+0.0%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markup$1,187.60+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (91). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (40 analysts) rates it buy, with a mean price target of $1461. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.